Finally, a study of 23 patients receiving TARE for metastatic breast cancer showed that increased frequency of baseline PD-1 expression by CD4+ TILs in the tumor microenvironment was associated with clinical response [99]. This evidence concerns the gene CD4 and neoplasm.